Monoclonal Antibodies Market 2020 - Pfizer Inc., Novartis AG, Bayer AG, Sanofi S.A., F. Hoffmann-La Roche AG, Eli Lilly and Co., Merck & Co., Inc

CMI analyses the Monoclonal Antibodies trends, by country, for a five year review period (2020-2027) forecast period. Our regular clients asked us to produce detailed market segmentation, and this is what you will find here: a report without any unnecessary padding, giving a unique analysis of the sector.

Major Companies Covered in this report:-
1 Pfizer Inc.*
2 Novartis AG.
3 Bayer AG.
4 Sanofi S.A.
5 Hoffmann-La Roche AG.
6 Eli Lilly and Co.
7 Merck & Co., Inc.
8 GlaxoSmithKline Plc.

Request For Sample Copy of the Report @
https://www.coherentmarketinsights.com/insight/request-sample/2403

Different monoclonal antibodies with unique mechanism of actions have been approved over the past few years, which work on immune checkpoints such as CTLA-4, PD-1, and PD-L1. Manufacturers are focusing on developing drugs belonging to various classes in order to treat variety of diseases ranging from cancer to rare diseases.

Rising incidence of cancer and other chronic diseases is a major factor that is expected to boost the monoclonal antibodies market growth over the forecast period. According to GLOBOCAN, in 2018, an estimated 43.6% new cases of breast cancer were registered in Asia Pacific. Also, according to the American Cancer Society, 2017, cancer was the second most common cause of death in the U.S., which accounted for around 1 out of every 4 deaths.

Get up to 30% Discount on this Premium Report @:
https://www.coherentmarketinsights.com/insight/request-discount/2403

Market players are focused on combining monoclonal antibodies with other therapies such as chemotherapy drugs, which is expected to assist the market growth over the forecast period. For instance, combination of nivolumab and ipilimumab for the treatment of intermediate- or poor-risk patients with previously untreated advanced renal cell carcinoma was approved in the U.S. in 2018 and in January 2019 in Europe.

Moreover, efforts of manufacturers to increase number of indications (oncology) for monoclonal antibodies is further expected to boost the market growth over the forecast period. For instance, in June 2018, the U.S. Food & Drug Administration (FDA) expanded the indication of pembrolizumab (Keytruda) to include recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.

Major players operating in the global monoclonal antibodies market include Pfizer Inc., Novartis AG, Bayer AG, Sanofi S.A., F. Hoffmann-La Roche AG, Eli Lilly and Co., Merck & Co., Inc., GlaxoSmithKline Plc., AbbVie Inc., Bristol-Myers Squibb, and Regeneron Pharmaceuticals Inc.

Apply Promo Code “STAYHOME” and Get Up to 30% Discount

If you purchase the report this year:

Buy This Complete A Business Report:
https://www.coherentmarketinsights.com/insight/buy-now/2403

Coherent Market Insights 1001 4th Ave,
#3200 Seattle, WA 98154,U.S.
Phone: US +1-206-701-6702/UK +44-020 8133 4027
Email: sales@coherentmarketinsights.com

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.